Journal of Neurology & Neurophysiology

ISSN - 2155-9562

Patricia J. McLaughlin

Patricia J. McLaughlin
Department of Neural & Behavioral Sciences,
500 University Drive, MCH109, Hershey, PA 17033-0850

  • Review Article
    Endogenous Opioids and the Treatment of Multiple Sclerosis
    Author(s): Ian S. Zagon and Patricia J. McLaughlinIan S. Zagon and Patricia J. McLaughlin

    Multiple sclerosis is an autoimmune disorder of the central nervous system that affects approximately 400,000 people in the United States and 2 million individuals worldwide. The disease is chronic, often progressive, and manifests through proliferation and activation of T-lymphocytes and astrocytes, resulting in demyelination and axonal damage. Approved therapies are interferon-based or involve T-cell immune modulators; however, many treatments have unacceptable side-effects, are cost-prohibitive, and/or require clinical visits for administration. There is an unmet need for disease-modifying therapies that are non-toxic and readily available. The regulatory pathway involving opioid growth factor (OGF) and its nuclear-associated receptor, OGFr, is involved in several autoimmune diseases including multiple sclerosis. The OGF-OGFr axis ap.. View More»

    DOI: 10.4172/2155-9562.S12-011

    Abstract PDF

Relevant Topics